ECMO is widely used in patients with refractory respiratory and/or circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thrombotic events is a key scientific issue that urgently needs to be addressed.
age older than 18 years old
received VV ECMO because of severe respiratory failure
anticoagulant contraindications
cerebral infarction or suspected patients
severe hypertension
women in gestational and lactational period
Parallel
Nafamostat
DrugNafamostat combined with unfractionated heparin for anticoagulation
Heparin
Drugunfractionated heparin for anticoagulation
incidence of ECMO related bleeding or thrombotic events
the incidence of ECMO related bleeding or thrombotic events,such as membrane oxygenator or tube thrombotic,local blooding.
Types and specific incidence rates of ECMO-related bleeding and thrombotic events
Time from ECMO initiation to bleeding and thrombotic events
ECMO duration
Blood product transfusion
Click on the lead sponsor to view all of their trials.
